This peptide inhibited TGF-1/Smad2/3 and STAT3 pathways, leading to decreased inflammation, tubular atrophy, myofibroblast activation, and fibrotic gene expression (Gwon et al., 2021)
Higher energy and stamina levels
The researcher behind several of these pilot publications has stated that the goal is to generate enough evidence to encourage the FDA to reconsider its policy on compounding BPC-157 the studies range in size from two to sixteen participants and do not include comparison groups
Treatment plans are often structured as two-month programs, which include one vial of BPC-157, a follow-up appointment, and lab testing to monitor progress and results
Diagnostic criteria for primary autoimmune cerebellar ataxia guidelines from an international task force on immune-mediated cerebellar ataxias
Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al